MX2020004435A - Compuestos inhibidores de tirosina cinasa de bruton (btk). - Google Patents

Compuestos inhibidores de tirosina cinasa de bruton (btk).

Info

Publication number
MX2020004435A
MX2020004435A MX2020004435A MX2020004435A MX2020004435A MX 2020004435 A MX2020004435 A MX 2020004435A MX 2020004435 A MX2020004435 A MX 2020004435A MX 2020004435 A MX2020004435 A MX 2020004435A MX 2020004435 A MX2020004435 A MX 2020004435A
Authority
MX
Mexico
Prior art keywords
btk inhibitor
inhibitor compounds
compounds
salts
compositions
Prior art date
Application number
MX2020004435A
Other languages
English (en)
Inventor
Jr Kenneth James Henry
Albert Khilevich
Steven Lee Kuklish
Katherine Marie Partridge
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2020004435A publication Critical patent/MX2020004435A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente invención se refiere a compuestos inhibidores de BTK, sales farmacéuticamente aceptables, composiciones farmacéuticas de los mismos, y métodos para usar estos compuestos, sales, o composiciones para tratar enfermedades autoinmunes tales como Artritis Reumatoide.
MX2020004435A 2017-11-06 2018-10-30 Compuestos inhibidores de tirosina cinasa de bruton (btk). MX2020004435A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2020004435A true MX2020004435A (es) 2020-08-06

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004435A MX2020004435A (es) 2017-11-06 2018-10-30 Compuestos inhibidores de tirosina cinasa de bruton (btk).

Country Status (34)

Country Link
US (1) US11542249B2 (es)
EP (1) EP3707133B1 (es)
JP (1) JP6920553B2 (es)
KR (1) KR102410202B1 (es)
CN (1) CN111278818B (es)
AR (1) AR113796A1 (es)
AU (1) AU2018360478B2 (es)
BR (1) BR112020006749A2 (es)
CA (1) CA3080123C (es)
CL (1) CL2020001089A1 (es)
CR (1) CR20200183A (es)
CY (1) CY1124994T1 (es)
DK (1) DK3707133T3 (es)
DO (1) DOP2020000103A (es)
EA (1) EA039398B1 (es)
EC (1) ECSP20024395A (es)
ES (1) ES2904843T3 (es)
HR (1) HRP20220178T1 (es)
HU (1) HUE057987T2 (es)
IL (1) IL273778B (es)
JO (1) JOP20200104A1 (es)
LT (1) LT3707133T (es)
MA (1) MA50561B1 (es)
MD (1) MD3707133T2 (es)
MX (1) MX2020004435A (es)
PE (1) PE20201168A1 (es)
PL (1) PL3707133T3 (es)
PT (1) PT3707133T (es)
RS (1) RS62805B1 (es)
SG (1) SG11202003178PA (es)
SI (1) SI3707133T1 (es)
TW (1) TWI694995B (es)
UA (1) UA126079C2 (es)
WO (1) WO2019089512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972603A1 (en) * 2019-05-23 2022-03-30 Novartis AG Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053269A1 (en) * 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Novel kinase inhibitors
CA3034600C (en) * 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
JP2014517016A (ja) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
WO2014093230A2 (en) 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
SG11202003178PA (en) 2020-05-28
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
EP3707133A1 (en) 2020-09-16
RS62805B1 (sr) 2022-02-28
LT3707133T (lt) 2022-01-25
CL2020001089A1 (es) 2020-10-23
AR113796A1 (es) 2020-06-10
CN111278818B (zh) 2023-03-28
ES2904843T3 (es) 2022-04-06
NZ764452A (en) 2023-09-29
JP6920553B2 (ja) 2021-08-18
DOP2020000103A (es) 2020-09-15
EA202090843A1 (ru) 2020-07-24
UA126079C2 (uk) 2022-08-10
AU2018360478B2 (en) 2020-09-17
PL3707133T3 (pl) 2022-04-04
CA3080123C (en) 2021-11-09
US11542249B2 (en) 2023-01-03
EA039398B1 (ru) 2022-01-24
JOP20200104A1 (ar) 2022-10-30
CR20200183A (es) 2020-05-30
IL273778A (en) 2020-05-31
MA50561B1 (fr) 2022-03-31
DK3707133T3 (da) 2022-01-03
KR20200060480A (ko) 2020-05-29
HUE057987T2 (hu) 2022-06-28
PT3707133T (pt) 2022-01-27
KR102410202B1 (ko) 2022-06-22
CY1124994T1 (el) 2023-01-05
HRP20220178T1 (hr) 2022-04-29
CN111278818A (zh) 2020-06-12
SI3707133T1 (sl) 2022-02-28
TW201930293A (zh) 2019-08-01
WO2019089512A1 (en) 2019-05-09
CA3080123A1 (en) 2019-05-09
MD3707133T2 (ro) 2022-07-31
MA50561A (fr) 2020-09-16
ECSP20024395A (es) 2020-06-30
PE20201168A1 (es) 2020-10-28
IL273778B (en) 2022-06-01
JP2021501749A (ja) 2021-01-21
EP3707133B1 (en) 2021-12-15
US20200290997A1 (en) 2020-09-17
TWI694995B (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
DOP2017000118A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
EA201892740A2 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
ECSP17028459A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201890072A1 (ru) Новые соединения в качестве модуляторов ror-гамма
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
MX2020004435A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
BR112017017594A2 (pt) dosagens de panobinostat para mieloma múltiplo
DOP2017000036A (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP18041935A (es) Inhibidores de ret